You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSotalol
Accession NumberDB00489  (APRD01230)
TypeSmall Molecule
GroupsApproved
Description

An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
4'-(1-Hydroxy-2-(isopropylamino)ethyl)methane sulfonanilideNot AvailableNot Available
beta-CardoneNot AvailableNot Available
SotalolFrench/German/SpanishINN
SotaloloNot AvailableDCIT
SotalolumLatinINN
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Betapacetablet80 mgoralBayer Health Care Pharmaceuticals Inc.1992-10-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Betapacetablet160 mgoralBayer Health Care Pharmaceuticals Inc.1992-10-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Betapacetablet120 mgoralBayer Health Care Pharmaceuticals Inc.1992-10-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochlorideinjection15 mg/mLintravenousMylan Institutional LLC2009-09-30Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sotalol Hydrochloridetablet120 mgoralTeva Pharmaceuticals USA Inc2000-05-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralTeva Pharmaceuticals USA Inc2000-05-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralTeva Pharmaceuticals USA Inc2000-05-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralTeva Pharmaceuticals USA Inc2000-05-05Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralGlobal Pharmaceuticals2000-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralGlobal Pharmaceuticals2000-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralGlobal Pharmaceuticals2000-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralGlobal Pharmaceuticals2000-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralEon Labs, Inc.2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralEon Labs, Inc.2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralEon Labs, Inc.2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralEon Labs, Inc.2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sorinetablet80 mgoralUpsher Smith Laboratories, Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sorinetablet120 mgoralUpsher Smith Laboratories, Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sorinetablet160 mgoralUpsher Smith Laboratories, Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sorinetablet240 mgoralUpsher Smith Laboratories, Inc.2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralMylan Pharmaceuticals Inc.2007-02-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralMylan Pharmaceuticals Inc.2007-02-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralMylan Pharmaceuticals Inc.2007-02-20Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralQualitest Pharmaceuticals2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralQualitest Pharmaceuticals2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralQualitest Pharmaceuticals2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralQualitest Pharmaceuticals2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralRebel Distributors Corp2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralLake Erie Medical DBA Quality Care Products LLC2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralAv Kare, Inc.2014-02-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralAv Kare, Inc.2014-02-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralAv Kare, Inc.2014-02-13Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralPd Rx Pharmaceuticals, Inc.2000-05-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralAidarex Pharmaceuticals LLC2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralPhysicians Total Care, Inc.2000-12-04Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralPhysicians Total Care, Inc.2006-03-14Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralPhysicians Total Care, Inc.2009-04-08Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sorinetablet80 mgoralCardinal Health2011-02-15Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralGolden State Medical Supply, Inc.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralGolden State Medical Supply, Inc.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralGolden State Medical Supply, Inc.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralGolden State Medical Supply, Inc.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralGolden State Medical Supply, Inc.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralGolden State Medical Supply, Inc.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralGolden State Medical Supply, Inc.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralApotex Corp.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralApotex Corp.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet240 mgoralApotex Corp.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralApotex Corp.2003-02-01Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralApotex Corp.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet120 mgoralApotex Corp.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet160 mgoralApotex Corp.2003-09-09Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralbryant ranch prepack2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralbryant ranch prepack2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralAmerican Health Packaging2013-06-12Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralAmerican Health Packaging2014-03-18Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotalol Hydrochloridetablet80 mgoralCarilion Materials Management2003-11-07Not AvailableUs 0a2ef1ad1c84951dc1392a8bbe1f3cb241c91ed59e44ad8268635315440d978c
Sotaloltablet80 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Sotaloltablet160 mgoralSivem Pharmaceuticals UlcNot AvailableNot AvailableCanada 5f16b84899037e23705f146ff57e3794121879cb055f0954756d94bc690476b4
Over the Counter ProductsNot Available
International Brands
NameCompany
BiosotalSanofi-Aventis
CardolAlphapharm
DarobAbbott
Darob miteAbbott
HipecorMerck
LoritmikKrka
RytmobetaAbbott
SotacorBristol-Myers Squibb
SotagardGlaxoSmithKline
SotalexBristol-Myers Squibb
SotaporBristol-Myers Squibb
TalozinAdeka
Tan ShiChia Tai Tianqing
Xi An LinChangzhou Pharmaceutical Factory
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sotalol Hydrochloride
959-24-0
Thumb
  • InChI Key: VIDRYROWYFWGSY-UHFFFAOYNA-N
  • Monoisotopic Mass: 308.096140945
  • Average Mass: 308.825
DBSALT000318
CategoriesNot Available
CAS number3930-20-9
WeightAverage: 272.364
Monoisotopic: 272.119463206
Chemical FormulaC12H20N2O3S
InChI KeyZBMZVLHSJCTVON-UHFFFAOYSA-N
InChI
InChI=1S/C12H20N2O3S/c1-9(2)13-8-12(15)10-4-6-11(7-5-10)14-18(3,16)17/h4-7,9,12-15H,8H2,1-3H3
IUPAC Name
N-(4-{1-hydroxy-2-[(propan-2-yl)amino]ethyl}phenyl)methanesulfonamide
SMILES
CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassSulfanilides
Direct ParentSulfanilides
Alternative Parents
Substituents
  • Sulfanilide
  • Aralkylamine
  • Aminosulfonyl compound
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonamide
  • Secondary alcohol
  • 1,2-aminoalcohol
  • Secondary amine
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm. Also for the treatment of documented life-threatening ventricular arrhythmias.
PharmacodynamicsSotalol is an antiarrhythmic drug. It falls into the class of beta blockers (and class II antiarrhythmic agents) because of its primary action on the β-adrenergic receptors in the heart. In addition to its actions on the beta receptors in the heart, sotalol inhibits the inward potassium ion channels of the heart. In so doing, sotalol prolongs repolarization, therefore lengthening the QT interval and decreasing automaticity. It also slows atrioventricular (AV) nodal conduction. Because of these actions on the cardiac action potential, it is also considered a class III antiarrhythmic agent. The beta-blocking effect of sotalol is non-cardioselective, half maximal at about 80mg/day and maximal at doses between 320 and 640 mg/day. Sotalol does not have partial agonist or membrane stabilizing activity. Although significant beta-blockade occurs at oral doses as low as 25 mg, significant Class Ieffects are seen only at daily doses of 160 mg and above.
Mechanism of actionSotalol has both beta-adrenoreceptor blocking (Vaughan Williams Class I) and cardiac action potential duration prolongation (Vaughan Williams Class I) antiarrhythmic properties. Sotalol is a racemic mixture of d- and l-sotalol. Both isomers have similar Class I antiarrhythmic effects, while the l-isomer is responsible for virtually all of the beta-blocking activity. Sotalol inhibits response to adrenergic stimuli by competitively blocking β1-adrenergic receptors within the myocardium and β2-adrenergic receptors within bronchial and vascular smooth muscle. The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells. The class II electrophysiologic effects are caused by an increase in sinus cycle length (slowed heart rate), decreased AV nodal conduction, and increased AV nodal refractoriness, while the class III electrophysiological effects include prolongation of the atrial and ventricular monophasic action potentials, and effective refractory period prolongation of atrial muscle, ventricular muscle, and atrio-ventricular accessory pathways (where present) in both the anterograde and retrograde directions.
AbsorptionIn healthy subjects, the oral bioavailability of sotalol is 90-100%. Absorption is reduced by approximately 20% compared to fasting when administered with a standard meal.
Volume of distributionNot Available
Protein bindingSotalol does not bind to plasma proteins.
Metabolism

Sotalol is not metabolized.

Route of eliminationExcretion is predominantly via the kidney in the unchanged form. Sotalol is excreted in the milk of laboratory animals and has been reported to be present in human milk.
Half lifeMean elimination half-life is 12 hours. Impaired renal function in geriatric patients can increase the terminal elimination half-life.
ClearanceNot Available
ToxicityThe most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2-16 grams) of sotalol the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachy-cardia, and premature ventricular complexes.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sotalol Action PathwayDrug actionSMP00660
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.995
Blood Brain Barrier+0.9382
Caco-2 permeable-0.8957
P-glycoprotein substrateNon-substrate0.6708
P-glycoprotein inhibitor INon-inhibitor0.8881
P-glycoprotein inhibitor IINon-inhibitor0.9638
Renal organic cation transporterNon-inhibitor0.9514
CYP450 2C9 substrateNon-substrate0.7392
CYP450 2D6 substrateNon-substrate0.8296
CYP450 3A4 substrateNon-substrate0.6194
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 substrateNon-inhibitor0.907
CYP450 2D6 substrateNon-inhibitor0.9231
CYP450 2C19 substrateNon-inhibitor0.9026
CYP450 3A4 substrateNon-inhibitor0.8807
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8276
Ames testNon AMES toxic0.9133
CarcinogenicityNon-carcinogens0.587
BiodegradationNot ready biodegradable0.9949
Rat acute toxicity2.2873 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.846
hERG inhibition (predictor II)Non-inhibitor0.8701
Pharmacoeconomics
Manufacturers
  • Academic pharmaceuticals inc
  • Bayer healthcare pharmaceuticals inc
  • Upsher smith laboratories inc
  • Amneal pharmaceutical
  • Apotex inc
  • Apotex inc etobicoke site
  • Impax pharmaceuticals
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injectionintravenous15 mg/mL
Tabletoral120 mg
Tabletoral160 mg
Tabletoral240 mg
Tabletoral80 mg
Prices
Unit descriptionCostUnit
Betapace AF 100 160 mg tablet Box538.2USD box
Betapace AF 60 120 mg tablet Bottle311.06USD bottle
Betapace 240 mg tablet8.94USD tablet
Sotalol hcl 150 mg/10 ml vial7.8USD ml
Betapace 160 mg tablet6.87USD tablet
Betapace af 160 mg tablet6.24USD tablet
Sorine 240 mg tablet5.6USD tablet
Betapace 120 mg tablet5.5USD tablet
Sotalol HCl 240 mg tablet5.29USD tablet
Sotalol 240 mg tablet5.09USD tablet
Betapace af 120 mg tablet4.99USD tablet
Sotalol HCl (AF) 160 mg tablet4.45USD tablet
Sorine 160 mg tablet4.31USD tablet
Sotalol af 160 mg tablet4.27USD tablet
Betapace 80 mg tablet4.12USD tablet
Sotalol HCl 160 mg tablet4.07USD tablet
Sotalol 160 mg tablet3.92USD tablet
Betapace af 80 mg tablet3.74USD tablet
Sotalol HCl (AF) 120 mg tablet3.56USD tablet
Sorine 120 mg tablet3.46USD tablet
Sotalol af 120 mg tablet3.42USD tablet
Sotalol HCl 120 mg tablet3.26USD tablet
Sotalol 120 mg tablet3.13USD tablet
Sotalol HCl 80 mg tablet2.67USD tablet
Sotalol HCl (AF) 80 mg tablet2.67USD tablet
Sorine 80 mg tablet2.61USD tablet
Sotalol af 80 mg tablet2.56USD tablet
Sotalol 80 mg tablet2.35USD tablet
Apo-Sotalol 160 mg Tablet0.68USD tablet
Co Sotalol 160 mg Tablet0.68USD tablet
Mylan-Sotalol 160 mg Tablet0.68USD tablet
Novo-Sotalol 160 mg Tablet0.68USD tablet
Nu-Sotalol 160 mg Tablet0.68USD tablet
Pms-Sotalol 160 mg Tablet0.68USD tablet
Ratio-Sotalol 160 mg Tablet0.68USD tablet
Sandoz Sotalol 160 mg Tablet0.68USD tablet
Apo-Sotalol 80 mg Tablet0.62USD tablet
Co Sotalol 80 mg Tablet0.62USD tablet
Mylan-Sotalol 80 mg Tablet0.62USD tablet
Novo-Sotalol 80 mg Tablet0.62USD tablet
Nu-Sotalol 80 mg Tablet0.62USD tablet
Pms-Sotalol 80 mg Tablet0.62USD tablet
Ratio-Sotalol 80 mg Tablet0.62USD tablet
Sandoz Sotalol 80 mg Tablet0.62USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point206.5-207 °CPhysProp
water solubilitySoluble (5510 mg/L)Not Available
logP0.24BURGOT,G ET AL. (1990)
Predicted Properties
PropertyValueSource
Water Solubility0.782 mg/mLALOGPS
logP0.85ALOGPS
logP-0.4ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)10.07ChemAxon
pKa (Strongest Basic)9.43ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area78.43 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity71.12 m3·mol-1ChemAxon
Polarizability29.34 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General Reference
  1. Waldo AL, Camm AJ, deRuyter H, Friedman PL, MacNeil DJ, Pauls JF, Pitt B, Pratt CM, Schwartz PJ, Veltri EP: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7-12. Pubmed
External Links
ATC CodesC07AA07
AHFS Codes
  • 24:24.00
PDB EntriesNot Available
FDA labelDownload (93.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AcetylcholineBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
AmifostineAntihypertensives may enhance the hypotensive effect of Amifostine.
BretyliumMay enhance the bradycardic effect of Bradycardia-Causing Agents. Bretylium may also enhance atrioventricular (AV) blockade in patients receiving AV blocking agents.
BupivacaineBeta-Blockers may increase the serum concentration of Bupivacaine.
ButabarbitalMay decrease the serum concentration of Beta-Blockers.
ButethalMay decrease the serum concentration of Beta-Blockers.
CarbacholBeta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.
DiazoxideMay enhance the hypotensive effect of Antihypertensives.
DipyridamoleMay enhance the bradycardic effect of Beta-Blockers.
DuloxetineHypotensive Agents may enhance the orthostatic hypotensive effect of DULoxetine.
FingolimodMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
FloctafenineMay enhance the adverse/toxic effect of Beta-Blockers.
HeptabarbitalMay decrease the serum concentration of Beta-Blockers.
HexobarbitalMay decrease the serum concentration of Beta-Blockers.
LacosamideBradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide.
MepivacaineBeta-Blockers may increase the serum concentration of Mepivacaine.
MethacholineBeta-Blockers may enhance the adverse/toxic effect of Methacholine.
MethohexitalMay decrease the serum concentration of Beta-Blockers.
MethylphenidateMay diminish the antihypertensive effect of Antihypertensives.
MidodrineBeta-Blockers may enhance the bradycardic effect of Midodrine.
MifepristoneMay enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.
ObinutuzumabAntihypertensives may enhance the hypotensive effect of Obinutuzumab.
PentobarbitalMay decrease the serum concentration of Beta-Blockers.
PentoxifyllineMay enhance the hypotensive effect of Antihypertensives.
PrimidoneMay decrease the serum concentration of Beta-Blockers.
PropafenoneMay enhance the arrhythmogenic effect of Antiarrhythmic Agents (Class III).
RegorafenibMay enhance the bradycardic effect of Beta-Blockers.
ReserpineMay enhance the hypotensive effect of Beta-Blockers.
RituximabAntihypertensives may enhance the hypotensive effect of RiTUXimab.
RivastigmineMay enhance the bradycardic effect of Beta-Blockers.
RuxolitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
SecobarbitalMay decrease the serum concentration of Beta-Blockers.
TadalafilMay enhance the antihypertensive effect of Antihypertensives.
TofacitinibMay enhance the bradycardic effect of Bradycardia-Causing Agents.
VardenafilMay enhance the antihypertensive effect of Antihypertensives.
YohimbineMay diminish the antihypertensive effect of Antihypertensives.
Food InteractionsNot Available

Targets

1. Potassium voltage-gated channel subfamily H member 2

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Potassium voltage-gated channel subfamily H member 2 Q12809 Details

References:

  1. Shimizu W, Antzelevitch C: Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation. 2000 Aug 8;102(6):706-12. Pubmed
  2. Numaguchi H, Mullins FM, Johnson JP Jr, Johns DC, Po SS, Yang IC, Tomaselli GF, Balser JR: Probing the interaction between inactivation gating and Dd-sotalol block of HERG. Circ Res. 2000 Nov 24;87(11):1012-8. Pubmed
  3. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R, Brugada R, Hong K, Bauersfeld U, Gaita F, Borggrefe M: Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. Pubmed
  4. Wolpert C, Schimpf R, Veltmann C, Giustetto C, Gaita F, Borggrefe M: Clinical characteristics and treatment of short QT syndrome. Expert Rev Cardiovasc Ther. 2005 Jul;3(4):611-7. Pubmed
  5. Fedida D, Orth PM, Hesketh JC, Ezrin AM: The role of late I and antiarrhythmic drugs in EAD formation and termination in Purkinje fibers. J Cardiovasc Electrophysiol. 2006 May;17 Suppl 1:S71-S78. Pubmed

2. Beta-1 adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Beta-1 adrenergic receptor P08588 Details

References:

  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. Pubmed
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. Pubmed
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. Pubmed
  4. Doggrell SA: The effects of (/-)-, ()-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. Pubmed
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. Pubmed
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed

3. Beta-2 adrenergic receptor

Kind: protein

Organism: Human

Pharmacological action: yes

Actions: antagonist

Components

Name UniProt ID Details
Beta-2 adrenergic receptor P07550 Details

References:

  1. Lowe MD, Lynham JA, Grace AA, Kaumann AJ: Comparison of the affinity of beta-blockers for two states of the beta 1-adrenoceptor in ferret ventricular myocardium. Br J Pharmacol. 2002 Jan;135(2):451-61. Pubmed
  2. Joseph SS, Lynham JA, Colledge WH, Kaumann AJ: Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):525-32. Epub 2004 Apr 2. Pubmed
  3. Yalcin I, Choucair-Jaafar N, Benbouzid M, Tessier LH, Muller A, Hein L, Freund-Mercier MJ, Barrot M: beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25. Pubmed
  4. Doggrell SA: The effects of (/-)-, ()-, and (-)-atenolol, sotalol, and amosulalol on the rat left atria and portal vein. Chirality. 1993;5(1):8-14. Pubmed
  5. Juberg EN, Minneman KP, Abel PW: Beta 1- and beta 2-adrenoceptor binding and functional response in right and left atria of rat heart. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):193-202. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 21, 2014 12:54